Insys cannabidiol tagged an Orphan Drug

|About: Insys Therapeutics, Inc. (INSY)|By:, SA News Editor

The FDA designates Insys Therapeutics' (INSY) pharmaceutical cannabidiol an Orphan Drug for the treatment of Lennox-Gastaut Syndrome, a severe form of childhood-onset epilepsy characterized by multiple seizure types, moderate-to-severe cognitive impairment and an abnormal EEG.

Orphan Drug designation affords the developer certain incentives including extended marketing exclusivity.